ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has a 1 Year Target Estimate of $21. The stock traded with the volume of 3.04 Million in the last trading session. ZIOPHARM Oncology Inc opened at $6.85 and closed by showing a decrease of -0.73%. The Bid price in the last session was $6.51 x 1000 and the Ask price was $7.22 x 2000. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).
ZIOPHARM Oncology Inc has the Market Capitalization of 881.94 Million. The Stock has its 52-week High of $13.08 and 52-Week Low of $4.45 and it touched its 52-week high on Dec 2, 2015 and 52-Week Low on Jul 25, 2016.
ZIOPHARM Oncology Inc reported its last Earnings on Nov 03 AMC where the company reported Actual EPS of $-0.11/Share whereas, the Analyst Estimated EPS was $-0.11/share. The difference between Actual EPS and Estimated EPS was $0/share. This represented an Earnings Surprise of 0%. The company will report its next earnings on Feb 22 – Feb 27 (Est.).
1 number of analysts also provided their insight on ZIOPHARM Oncology Inc, where the Average Price Target for the stock is $21. They also projected Low Price Target as $21 while High Price Target is set at $21.
A number of analysts rated the stock as well: 1 analysts believe that the stock is a STRONG BUY while 0 reported it as Buy.4 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 0 say that this stock is a SELL.
ZIOPHARM Oncology Inc annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 0. The company has its Price to Sales (P/S) ratio of 123.69 where Price to Book (P/B) ratio of 0, Price to Cash Per share (P/C) of 9.4 and Price to Free Cash Flow (P/FCF) has a value of 0.
The company has its Return on Assets (ROA) of -123.7 Percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) displays a value of -137.4%.
The stock is currently trading at Distance from 20-Day simple moving Average of 6.33% whereas, Distance from 50-Day Simple moving average is 15.43 Percent and Distance from 200-Day Simple Moving Average of 4.75 percent.
A look at performance overview of ZIOPHARM Oncology Inc depicts that Performance (Week) is 5.46 percent while Performance Month is 24.72%. Quarterly performance shows a value of 30.5% and Half Year Performance value stands at -12.66%. Yearly performance of the stock has the value of -48.32 percent. ZIOPHARM Oncology Inc has its YTD performance of -18.65 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).
Many Insiders have done trades inside the company. The latest trade was made on 31 May 2016 where Chief Operating Officer Belbel (Caesar J) did a transaction type “Sell” in which 6667 shares were traded at a price of $7.74. Another insider trade includes Chief Executive Officer Cooper (Laurence James Neil) who also initiated a transaction in which 116667 shares were traded on 4 May 2016 as “Sell”. On 20 Apr 2016 Director Cannon (James Anthony) traded 15000 shares as “Buy” at $5.01. Director Weiser (Michael) Buy 15000 shares on 18 Apr 2016 at the price of $5.01.
The latest Upgrades/Downgrades was done by Research firm Wells Fargo on 10-Aug-16 who Upgrade the stock from Underperform to Market Perform. Other firms have also Upgraded/Downgraded the stock. On 2-Jun-16, Raymond James took an action “Initiated” to Mkt Perform. On 10-Mar-15, the stock was Downgrade to Neutral by Mizuho.